NCT06116045 - Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women with Sexual Arousal Disorder | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

February 1, 2025

Study Completion Date

March 31, 2025

Conditions

Female Sexual Arousal DisorderFemale Sexual Dysfunction

Interventions

DRUG

BZ371A 7.5 mg (1.5 ml)

7.5 mg gel

DRUG

BZ371A 5.0 mg (1.0 ml)

5.0 mg gel

DRUG

BZ371A 2.5 mg (0.5 ml)

2.5 mg gel

DRUG

Placebo (1.5 ml)

BZ371A-matched placebo

DRUG

Placebo (1.0 ml)

BZ371A-matched placebo

DRUG

Placebo (0.5 ml)

BZ371A-matched placebo

Trial Locations (1)

RECRUITING

Centro de Pesquisa Clínica Multiusuário (CePeM), Rio de Janeiro